Dopaminergic Therapy for Restless Legs Syndrome/Willis-Ekbom Disease.

Sleep Med Clin

Department of Neurology, Vanderbilt University Medical Center, 2220 Pierce Avenue, Nashville, TN 37232, USA.

Published: September 2015

Dopaminergic therapies have been a mainstay of restless legs treatment and are endorsed as first-line therapies by multiple professional societies. This article summarizes the differences and similarities among the dopamine agonists with attention to pharmacology, efficacy, side effects, and dosing.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jsmc.2015.05.012DOI Listing

Publication Analysis

Top Keywords

restless legs
8
dopaminergic therapy
4
therapy restless
4
legs syndrome/willis-ekbom
4
syndrome/willis-ekbom disease
4
disease dopaminergic
4
dopaminergic therapies
4
therapies mainstay
4
mainstay restless
4
legs treatment
4

Similar Publications

Introduction: In Parkinson's disease (PD), sleep-wake problems are disease-related symptoms that occur throughout the day and have a negative impact on patients' quality of life to an extent that is equal to or greater than that of typical motor symptoms.

Areas Covered: Insomnia due to fragmented sleep and excessive daytime sleepiness (EDS) worsen as PD progresses. Nighttime wearing-off and early morning-off should be considered first when fragmented sleep is reported in PD patients.

View Article and Find Full Text PDF

Study Objectives: This study aimed to investigate the effect of dopamine agonists (DA) and Clonazepam on Large Muscle Group Movements during sleep (LMM), a distinct motor phenomenon, in Restless Legs Syndrome (RLS).

Methods: A retrospective analysis was conducted on 51 drug-free adult patients with RLS, divided into three groups: 33 received a DA (pramipexole or ropinirole), 15 received clonazepam, and 18 received a placebo. Each patient underwent two consecutive nocturnal polysomnographic (PSG) recordings: one baseline and one following treatment administration.

View Article and Find Full Text PDF

Objective: This study aims to asess alexithymia, anger and its expression, sensitivity to bodily sensations, personality, and their relationship with the severity of the disease in patients with Restless Legs Syndrome.

Method: The study included 63 patients diagnosed with Restless Legs Syndrome and 63 age, gender and education matched controls. All participants were given, Toronto Alexithymia Scale, Somatosensory Amplification Scale, The State Trait Anger Scale and Temperament and Character Inventory.

View Article and Find Full Text PDF

Introduction: Restless legs syndrome (RLS) is a frequently encountered neurological illness that has no effective treatment and imposes an enormous socioeconomic burden. Autophagy is essential for the maintenance of healthy cellular physiology, cell viability, and defense against pathogenic conditions. However, there is no study investigating the possible role of autophagy-related proteins (ATGs) in RLS patients.

View Article and Find Full Text PDF

The complexities in the differential diagnosis of restless legs syndrome (Willis-ekbom disease).

Expert Rev Neurother

January 2025

Basic and Clinical Neuroscience department, The Maurice Wohl Clinical Neuroscience Institute, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.

Introduction: We present a literature review on the clinical conundrums surrounding the differential diagnosis of restless legs syndrome (RLS, Willis Ekbom disease), as well as conditions that can mimic RLS. An extensive literature search showed that secondary causes of RLS ranged from commonly recognized causes, such as iron deficiency anemia, to less widely noted causes, such as rheumatoid disorders and hypothyroidism. There is a controversial association with Parkinson's disease, essential tremor and RLS, whereby RLS is proposed as a prodromal feature.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!